Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

CDC officials said they opted to upgrade the advisory after seeing more patients whose illness cannot be traced back to an infected animal or bird. "That's a newer finding in the history of H5 - not ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...